A son of glembatumumab vedotin has just started its phase 1 study.
ApexOnco Front Page
Recent articles
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
But the Astra/Daiichi ADC stumbles in lung cancer.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
The company quietly deprioritises AlphaMedix.
The company is starting four new pivotal trials this year.
Cafelkibart’s entry into phase 3 is of note to Coherus.
Tecvayli and Hernexeos might get speedy approval decisions.
